FDA panel against higher dose of Lilly-Incyte arthritis drug

(Reuters) - An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

from Reuters: Health News https://ift.tt/2KbU1EK
via IFTTT